

January 20, 2022

News Release

MSD K.K.
KYORIN Holdings, Inc.

**MSD K.K. receives manufacturing and marketing approval of
LYFNUA[®] Tablets, world's first selective P2X3 receptor antagonist
for the treatment of chronic cough**

MSD K.K. (head office: Chiyoda-ku, Tokyo; Representative Director and President: Kyle Tattle; "MSD") received on January 20 approval in Japan to manufacture and market Lyfnua[®] Tablets 45 mg (gefapixant citrate), a selective P2X3 receptor antagonist for the treatment of cough.

Lyfnua[®] Tablets will be distributed solely by KYORIN Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; "KYORIN"), a subsidiary of KYORIN Holdings, Inc. (head office: Chiyoda-ku, Tokyo; President and CEO: Yutaka Ogihara), under an exclusive distribution agreement with MSD's affiliate company.

As the world's first approved selective P2X3 receptor antagonist, Lyfnua[®] Tablets inhibit extracellular ATP signaling via P2X3 receptors found on vagal C fibers in the airway and reduce sensory nerve activation and cough. It is indicated for refractory chronic cough.

MSD will continue to develop innovative medicines and vaccines that address unmet medical needs and invent for life.

KYORIN will expand its product portfolio in its strategic respiratory field by exclusively distributing Lyfnua[®] Tablets, aiming to further increase its presence in this area and contribute to the treatment of chronic cough.

Inquiries	
MSD K.K. Kinji Iwase, Communications, Kitanomaru Square, 1-13-12, Kudankita, Chiyoda-ku, Tokyo 102-8667 Mobile: 03-6272-1001 e-mail: kinji.iwase@merck.com	KYORIN Holdings, Inc. Yoshinori Tanifuji, Management Strategy & Planning Division Corporate Planning 6, Kanda-Surugadai, 4-chome, Chiyoda-ku, Tokyo 101-8311 TEL: 03-3525-4707 FAX: 03-3525-4777 e-mail: kyorin-home@kyorin-gr.co.jp

Related information

Lyfnua® Tablets 45 mg, selective P2X3 receptor antagonist for the treatment of cough

Trade name	Lyfnua® Tablets 45 mg
Generic name	Gefapixant citrate
Indications	Refractory chronic cough
Dosage and administration	Normally for adults, 45 mg of gefapixant is administered orally twice daily.
Application date	February 26, 2021
Approved date	January 20, 2022